Riskpilot← Back to searchSign inGet full accessCONRIG PHARMA ApS
APSActiveCVR 33373236Fagerparken 33Manufacture of pharmaceutical preparations · NACE 2120Est. 2010— employees
Revenue 2025
DKK -99K
+8% vs 2024
EBITDA margin
100.0%
-8% vs 2024
Equity ratio
—
Financial strength
Net profit 2025
DKK -96K
+4% vs 2024
| Revenue | DKK -99K | +8% |
| EBITDA | DKK -99K | -8% |
| Net profit | DKK -96K | +4% |
| Total assets | DKK 66K | -6% |
| Equity | DKK 0 | -100% |
| Employees | — | — |
Legal name
CONRIG PHARMA ApS
CVR number
33373236
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
20. december 2010
Share capital
DKK 123.802
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to medlemmer af bestyrelsen i forening med en direktør, eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed med udvikling, produktion, markedsføring og salg af lægemidler og dermed beslægtet virksomhed.
Address
Fagerparken 33
Phone
+4524601215
Email
niels.skjaerbaek@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -266 | -228 | -93 | -89 | -684 | -305 | -388 | -165 | -555 | -246 | 1.266 | -506 | -92 | -99 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -266 | -228 | -93 | -89 | -684 | -305 | -388 | -165 | -555 | -246 | 1.266 | -516 | -92 | -99 |
| Depreciation & amort. | -16 | -48 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -282 | -276 | -93 | -89 | -684 | -305 | -388 | -165 | -555 | -246 | 1.266 | -516 | -92 | -99 |
| Net financials | 1 | 1 | 1 | -0 | 0 | -7 | -18 | -33 | -48 | -62 | -21 | 5 | -8 | 3 |
| Profit before tax | -281 | -274 | -92 | -89 | -684 | -311 | -405 | -198 | -604 | -308 | 1.245 | -511 | -100 | -96 |
| Tax | -37 | -0 | -10 | -15 | -153 | -25 | -7 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -244 | -274 | -81 | -74 | -531 | -286 | -398 | -198 | -604 | -308 | 1.245 | -511 | -100 | -96 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 230 | 302 | 209 | 640 | 273 | 139 | 97 | 226 | 250 | 53 | 1.195 | 39 | 69 | 66 |
| Equity | 200 | 276 | 94 | 620 | 90 | -197 | -595 | -793 | -1.397 | -1.705 | 409 | -102 | 25 | 0 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 30 | 27 | 115 | 20 | 183 | 335 | 692 | 1.019 | 1.646 | 1.758 | 786 | 140 | 45 | 66 |
| Total debt | 30 | 27 | 115 | 20 | 183 | 335 | 692 | 1.019 | 1.646 | 1.758 | 786 | 140 | 45 | 66 |
EBITDA margin
-9893600.0%
This company
15.8%
Market median
-62617822% vs market
20122025
Equity ratio
0.0%
This company
38.2%
Market median
-100% vs market
20122025
Return on equity
-9578600.0%
This company
18.4%
Market median
-52057709% vs market
20122025
Net profit margin
-9578600.0%
This company
8.1%
Market median
-118254421% vs market
20122025
Asset turnover
-1.51×
This company
1.12×
Market median
-235% vs market
20122025
Debt / equity
65517.00×
This company
0.62×
Market median
-10567158% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MS Management | Management | 2010 | — | — |
LC Management | Management | 2022 | — | — |
SK Management | Management | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2011 | — | — | |
| Chairman | 2011 | — | — | |
| Chairman | 2015 | — | — | |
| Board of Directors | 2015 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2022 | |
JBHA Holding ApS | Company | 33.3% | 33.3% | 2019 |
FAB5 Holding ApS | Company | 25.0% | 25.0% | 2015 |
Thomsen Pharma ApS | Company | 33.3% | 33.3% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of CONRIG PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mikael Søndergaard Thomsen | Management | 0 companies |
| Lars Christer Fredrik Fåhraeus | Management | 0 companies |
| Snickar Karl Johan Tobieson | Management | 0 companies |
| Frank Knudsen | Board of Directors | 0 companies |
| Else Sissel Vorstrup | Chairman | 0 companies |
| John Bondo Hansen | Chairman | 0 companies |
| Niels Skjærbæk | Board of Directors | 0 companies |